Entrada Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $203.51M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | Before market open | $900.00K | $-1.01 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $900.00K | $-0.95 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $1.30M | $-0.94 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | $1.60M | $-1.06 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | Before market open | $2.00M | $-1.04 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | $20.60M | $-0.42 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | Before market open | $37.40M | $0.03 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 5, 2024 | Before market open | $19.60M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 13, 2024 | Before market open | – | – | – |
Press releases
Announcements Entrada Therapeutics filed with the SEC
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Meet Andrew and JJ, living with Duchenne muscular dystrophy
Regulation FD disclosure · EX-99.1 to Form 8-K
Entrada Therapeutics Reports First Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Entrada Therapeutics Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Entrada Therapeutics Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D. to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Entrada Therapeutics Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
2025 J.P. Morgan Healthcare Conference NASDAQ: TRDA
Results of operations · Other events · EX-99.1 to Form 8-K
Entrada Therapeutics Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Entrada Therapeutics Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Announces $100 Million Registered Direct Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Entrada Therapeutics Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Entrada Therapeutics Announces Updates on ENTR-601-44
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Entrada Therapeutics Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Therapeutics Receives Authorization in the United Kingdom to
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Entrada Therapeutics Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy
Other events · EX-99.1 to Form 8-K
Vertex and Entrada Therapeutics Establish Collaboration
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Entrada Therapeutics Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Entrada Therapeutics Reports First Quarter 2022
Results of operations · EX-99.1 to Form 8-K
Reports Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
Entrada Therapeutics Reports Third Quarter 2021
Results of operations · EX-99.1 to Form 8-K